Emmanuelle Mouret‐Fourme

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Daniel R. Barnes, Matti A. Rookus, Lesley McGuffog et al. · Genetics in Medicine · 2020 · 145 citations · Full text

Life Sciences, Genetics, Oncology +17

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis

Claire Bonneau, Gilles Paintaud, Olivier Trédan et al. · European Journal of Cancer · 2018 · 95 citations

Medicine, Immunology, Oncology +7

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results

Jacques Rouëssé, Brigitte De La Lande, F. Bertheault-Cvitkovic et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 75 citations

Medicine, Oncology, Radiation Oncology +16

Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i>/<i>2</i> Mutation Carriers: A Mendelian Randomization Study

Frank Qian, Shengfeng Wang, Jonathan S. Mitchell et al. · JNCI Journal of the National Cancer Institute · 2018 · 74 citations · Full text

Life Sciences, Genetics, Oncology +17

miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness

Florence Lerebours, Géraldine Cizeron-Clairac, A. Susini et al. · International Journal of Cancer · 2013 · 72 citations

Medicine, Cancer Biology, Oncology +17